Sangamo Therapeutics, Inc.
News
Sangamo Therapeutics Second Quarter 2024 Earnings: Misses Expectations
Simply Wall St Sangamo Therapeutics ( NASDAQ:SGMO ) Second Quarter 2024 Results Key Financial Results Revenue: US$356.0k (down 95...\n more…
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago. These...\n more…
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
Business Wire Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and second quarter 2024 financial results. Sangamo has demonstrated important progress over...\n more…
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement.\nThe post Why Is...\n more…
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
Business Wire Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously...\n more…